OncoSil Medical Limited Stock price

Equities

OSL

AU000000OSL3

Biotechnology & Medical Research

Market Closed - Australian S.E. 07:06:56 2024-03-27 pm EDT 5-day change 1st Jan Change
0.005 AUD 0.00% Intraday chart for OncoSil Medical Limited -28.57% -44.44%
Sales 2022 1.06M 693K Sales 2023 1.47M 956K Capitalization 23.71M 15.45M
Net income 2022 -10M -6.52M Net income 2023 -11M -7.17M EV / Sales 2022 27 x
Net cash position 2022 10.98M 7.15M Net cash position 2023 9.22M 6.01M EV / Sales 2023 9.87 x
P/E ratio 2022
-3.02 x
P/E ratio 2023
-1.2 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 46.22%
More Fundamentals * Assessed data
Dynamic Chart
1 week-28.57%
Current month-37.50%
1 month-37.50%
3 months-44.44%
6 months-44.44%
Current year-44.44%
More quotes
1 week
0.01
Extreme 0.005
0.01
1 month
0.01
Extreme 0.005
0.01
Current year
0.01
Extreme 0.005
0.01
1 year
0.01
Extreme 0.005
0.02
3 years
0.01
Extreme 0.005
0.11
5 years
0.01
Extreme 0.005
0.22
10 years
0.01
Extreme 0.005
0.28
More quotes
Managers TitleAgeSince
Chief Executive Officer - 20-05-03
Director of Finance/CFO - 23-05-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Executive Officer - 20-05-03
Chairman - 23-08-06
Director/Board Member - 23-07-13
More insiders
Date Price Change Volume
24-03-27 0.005 0.00% 660 000
24-03-27 0.005 -16.65% 2,327,785
24-03-26 0.005999 0.00% 704,910
24-03-25 0.005999 0.00% 2,066,536
24-03-22 0.005999 -14.30% 917,406

Delayed Quote Australian S.E., March 27, 2024 at 07:06 pm EDT

More quotes
OncoSil Medical Ltd is an Australia-based medical device company seeking to advance radiation for cancer patients. The Company is focused on the development and commercialization of its lead product candidate, OncoSil localized radiation therapy, for the treatment of pancreatic and distal cholangiocarcinoma. OncoSil is a targeted radioactive isotope (Phosphorus-32), implanted directly into a patient's pancreatic tumors through an endoscopic ultrasound. OncoSil is a single-use brachytherapy device that has received breakthrough device designation in the European Union, the United Kingdom, and the United States for the treatment of unresectable locally advanced pancreatic cancer in combination with chemotherapy. OncoSil comprises phosphorous-32 microparticles suspended in a specially formulated diluent. OncoSil is indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy.
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock OncoSil Medical Limited - Australian S.E.